US Stock MarketDetailed Quotes
GENE Genetic Technologies
- 0.775
- +0.064+9.06%
Close Aug 9 16:00 ET
- 0.775
- 0.0000.00%
Post 20:01 ET
2.49MMarket Cap-5166P/E (TTM)
0.799High0.737Low13.04KVolume0.737Open0.711Pre Close9.93KTurnover1.69%Turnover RatioLossP/E (Static)3.22MShares4.65052wk High1.21P/B596.36KFloat Cap0.70152wk Low--Dividend TTM769.50KShs Float1385.000Historical High--Div YieldTTM8.73%Amplitude0.701Historical Low0.761Avg Price1Lot Size
About Genetic Technologies Company
Genetic Technologies Ltd. Is a molecular diagnostic company that provides predictive testing and assessment tools to help doctors proactively manage women's health. It operates in geographical segments in the United States and Australia. The company's product, BREVAGenplus, is a clinically proven non-hereditary breast cancer risk assessment test. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Company Profile
SymbolGENE
Company NameGenetic Technologies
Listing DateSep 2, 2005
Founded1987
CEOMr. Simon Morriss
MarketNASDAQ
Employees60
Securities TypeDR
ADS Ratio1.0 : 30.0
Fiscal Year Ends06-30
Address60-66 Hanover Street
CityFitzroy
ProvinceVictoria (VIC)
CountryAustralia
Zip Code3065
Phone61-3-8412-7000
Websitehttp://www.genetype.com
Company Executives
- Name
- Position
- Salary
- Simon Morriss
- Chief Executive Officer
- 587.74K
- Kevin Camilleri
- Chief Executive Officer, EasyDNA
- 281.15K
- Carl Stubbings
- Chief Commercial Officer
- 296.94K
- Tony Di Pietro
- Company Secretary and Chief Financial Officer
- 184.43K
- Dr. Richard Allman
- Chief Scientific Officer
- 87.28K
- Peter Rubinstein
- Non-Executive Chairman of the Board
- 164.72K
- Dr. Jerzy Muchnicki
- Director
- 64.46K
- Dr. Lindsay P. Wakefield
- Independent Director
- 74.55K
- Nicholas Burrows
- Independent Director
- 74.55K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg